Core Insights - The report focuses on the independent market research of the Chinese cosmetics raw materials industry for 2025, analyzing the current status and trends from multiple dimensions [1] - The demand for high-quality and innovative raw materials is increasing due to consumers' rising expectations for safety and efficacy, driven by advancements in biotechnology and green chemistry [1][6] Market Overview - The global cosmetics raw materials market was valued at $88.56 billion in 2019 and is projected to reach $114.24 billion by 2024, with a CAGR of 5.2%. By 2029, it is expected to grow to $169.43 billion at a CAGR of 8.2% [21][23] - The Chinese cosmetics raw materials market was valued at ¥114.78 billion in 2019, expected to grow to ¥160.39 billion by 2024, with a CAGR of 5.7%. By 2029, it is projected to reach ¥256.18 billion at a CAGR of 8.6% [25][27] Industry Trends - Future trends include a revolution in raw materials driven by biotechnology, an upgrade in precise skincare demands, a deepening commitment to sustainable development, and accelerated policy support for technology transformation [2][31] - The industry has undergone several iterations, evolving from natural raw materials to synthetic, efficacy-driven, and now to biotechnology-driven solutions [10][9] Competitive Landscape - The global market is concentrated in Europe, America, and the Asia-Pacific region, with Chinese companies like Weiqi Technology excelling in peptide fields [2][33] - Major players include BASF, Lubrizol, Croda, and DSM, each with unique competitive advantages in various segments of the cosmetics raw materials market [34] Business Models - The business models in the cosmetics raw materials industry include raw material sales, customized services, and joint research and development, with a growing emphasis on service-oriented models [14][16] - Companies are increasingly offering customized raw materials and collaborative R&D to reduce inventory costs for smaller brands [14] Regulatory Environment - Continuous policy support and regulation are fostering a conducive environment for innovation in the cosmetics raw materials market, with an increasing number of new raw material registrations [17][29] - The Chinese regulatory framework has been evolving to enhance the safety and efficacy of cosmetics, promoting a more transparent and standardized industry [29] Technological Innovations - Advances in biotechnology, nanotechnology, and green manufacturing are driving the development of new raw materials, enhancing their efficacy and safety [19][18] - The integration of AI in formulation design and the use of sustainable production processes are reshaping the industry landscape [31][19]

近日，开拓药业宣布，其外用雄激素受体（AR）拮抗剂KX-826与米诺地尔联合治疗中国成年男性脱发临床观察试 验，已达到主要研究终点。这份至关重要的临床数据结果迅速引发市场关注，当日公司跳涨9.17%，表现亮眼。 与此同时，公司具有美白祛斑功能的功效性化妆品原料KT -939正式启动全球销售业务，并已于近期成功完成首份原料 销售，是唯一入选2025纽约化妆品原料展（NYSCC）Inspiration Hive展区的"中国成分"。 在经历过诸多波折后，公司终于接连迎来好消息。根据WIND数据显示，截至5月22日，开拓药业年内累计涨幅达到 47.42%。 如今，在医药与消费结合的新趋势下，开拓药业正在通过"外用创新药研发+化妆品产品业务+化妆品原料业务"三驾马 车驱动转型。在脱发治疗这个兼具医疗刚需与消费属性的赛道，KX-826如何构建差异化的竞争壁垒？面对全球生物医 药行业经历估值重构的当下，功效性化妆品原料和产品的国际突围又暗藏哪些商业密码？ 值此战略转型关键节点，格隆汇深度对话开拓药业创始人、董事长兼CEO童友之博士，解码转型战略逻辑，探寻穿越 周期的生存智慧。 数据来源： WIND ，格隆汇整理 数据截至 ...

欧莱雅集团于5月23日宣布，与中国创新生物技术公司未名拾光（Veminsyn）达成战略合作，将对其进 行少数股权投资。双方将建立战略合作伙伴关系，共同研发创新生物活性成分，并推动其规模化生产， 以及采用低碳生物制造技术开发化妆品原料。此次投资将会是欧莱雅中国旗下上海美次方投资有限公司 最新的一笔开放式创新投资，并获得欧莱雅集团战略创新风险投资基金公司BOLD（Business Opportunities for L'Oréal Development）支持。未名拾光也是2023年"欧莱雅BIG BANG美妆科技共创计 划" (BIG BANG)的优胜企业。 ...

证券代码：301076 证券简称：新瀚新材 江苏新瀚新材料股份有限公司 投资者关系活动记录表 编号：2025-001 | 投资者关系活动类别 | 特定对象现场调研 | 分析师会议 | | --- | --- | --- | | | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | ☑其他 现场参观 | 线上会议 | | 参与单位名称及人员姓名 | 民生证券-完颜尚文 | 中泰证券-王鹏 | | | 国海证券-李娟廷 | 天风证券-杨滨钰 | | | 申银万国证券-李绍程 邵靖宇 | | | | 耕霁（上海）投资-曹慧 张林晚 | | | | 上海嘉世私募基金-周盘棋 | 红土创新基金-李传鹏 | | | 华福证券-孙范彦卿 | 金科投资-李翌 | | | 天风证券-杨滨钰 | 西部利得基金-陈雨 | | | 远信投资-杨大志 | 北京宏道投资-段然 | | | 深圳前海华杉投资-申玉婷 | | | 时间 | 2025 年 4 月 28 日 16:00-16:30 | | | 地点 | 线上会议 | | | 上市公司接待人员姓名 | 董事会秘书：李翔飞 | | | | 财 ...

Core Insights - Despite an 11.88% year-on-year decline in revenue to 5.677 billion yuan, the company achieved a significant profit rebound, with total profit increasing by 159.94% to 241 million yuan and net profit attributable to shareholders rising by 122.17% to 103 million yuan, successfully reversing previous losses [1] - The company aims to become a global leader in chemical and technology solutions, focusing on differentiated development and enhancing core competitiveness through a strategy of "focus, foresight, and alliances" [1] Business Segments - The crop protection segment remains the core pillar, contributing 3.590 billion yuan, accounting for 63.25% of total revenue. The company has established a supply chain system covering the entire product lifecycle through its production bases in China, the UK, and Malaysia [2] - The pharmaceutical CDMO segment generated revenue of 1.285 billion yuan, benefiting from the growing demand for outsourced R&D in innovative drugs. The company has formed partnerships with several leading pharmaceutical firms and is expanding its CRO platform [2] Future Strategy - The company plans to expand mature businesses, including small molecule CDMO, starting materials, GMP intermediates, and advanced raw materials. It will also invest in emerging businesses such as peptide CDMO and radioactive drug-related CDMO [3] - Despite revenue pressures, the company maintains a strong commitment to R&D, with R&D expenses reaching 291 million yuan, accounting for 5.13% of revenue. The company holds 160 domestic and international invention patents [3] International Strategy - The company's overseas strategy is proactive, with the UK base serving as a gateway to the European market and the Malaysian project as a key foothold in Southeast Asia. This multi-regional capacity configuration reduces geopolitical risks and allows for customized solutions based on client needs [3] Shareholder Returns - The company returned nearly 98 million yuan to shareholders through cash dividends and share buybacks, representing 94.84% of net profit, demonstrating management's commitment to investor returns [4] - The company has implemented a mechanism for shared interests between shareholders and employees, binding core talent through capital increases and employee stock ownership plans [4] Outlook - The company is positioned for a higher quality leap as a "chemical solutions provider," warranting continued market attention [5]

4月25日，新瀚新材（301076）(301076.SZ)发布2024年年报，公司不仅在化妆品原料和光引发剂等多类 产品上实现增长，其现金流更是创下上市后新高。 证券之星李若菡 证券之星注意到，作为PEEK单体核心原料DFBP国内少数实现规模化生产的企业之一，新瀚新材凭借深 厚的研发积累与优质的客户结构，正在这一高景气赛道上稳健前行。面对下游应用需求的不断增加，公 司通过"产能提升+技术突破"双轮驱动，持续强化其在行业内的竞争优势。同时，公司将ESG理念融入 企业经营管理，持续提升ESG管理水平，推动公司高质量发展。 PEEK市场快速发展，核心业务增长动能强劲 公开资料显示，新瀚新材基于傅克反应生产各类芳香族酮类产品，包括特种工程塑料核心原料、光引发 剂和化妆品原料等，其下游应用领域主要为航空航天，涂料、油墨、化妆品以及医疗领域。 据2024年年报显示，新瀚新材全年实现营业收入4.19亿元，归母净利润为5597万元。其中，特种工程塑 料业务贡献突出，实现营收1.75亿元，占总营收比重超过四成。 公司生产的DFBP是制造PEEK(聚醚醚酮)的关键原料，随着PEEK应用场景的持续拓展，公司的特种工 程塑料业务将迎 ...

公告称，本次增持事项彰显童博士对公司的商业化前景及增长潜力的坚定信心以及对公司长期投资价值 的充分认可。集团将继续围绕皮肤科领域，深耕现有化妆品产品，拓宽产品覆盖场景，加快推动新化妆 品产品，进一步丰富产品矩阵。同时，考虑到功效性原料的市场潜力，公司正在积极开拓 KT-939 和 KX-826 化妆品原料市场，寻求与化妆品品牌商的合作机会，持续拓展化妆品塬料业务以培育新利润增 长点。 智通财经APP讯，开拓药业-B(09939)发布公告，该公司董事会主席、执行董事兼行政总裁童友之博士于 2025 年 3 月 28 日通过其全资拥有公司 KT International Investment Limited 于公开市场以自有资金 25.9 万 港元(平均成交价格为每股 1.295 港元)增持公司 20万 股股份，占公司于本公告日期已发行股本总额 约 0.0447%。此外，童博士行使了根据公司 2020 年雇员激励计划授予的 125万 份受限制股票单位(对应 公司 125万 股普通股)所赋予的权利。该等股票已于 2025 年 3 月 31 日完成归属。紧随本次增持事项 后，童博士于合共 4920.03万 股股份中 ...